Leo Foundation's new CIO looks forward to life without MIFID II

At the start of October, a top member of Danske Capital's team swapped his job at the Danish banking group for the foundation that owns Danish drugmaker Leo Pharma. The limits of MIFID II are now a thing of the past, says Morten Stampe Christensen.

Morten Stampe Christensen, new CIO at Leo Foundation. | Photo: LEO Foundation

So far, there will be nine people at the office party this Christmas at Morten Stampe's new workplace, Leo Foundation, best known for owning the Danish drug company Leo Pharma A/S.

Morten Stampe Christensen came from a position as Senior Vice President and Head of Asset Allocation and Macro at Danske Capital, but now he has turned his working life upside-down with his new job as of Oct. 1 this year.

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from AMWatch

Nasdaq reports record year in Europe

In 2021, the number of new equity listings on the Nasdaq exchange in Copenhagen broke the old record set in 2007, and in Stockholm, the exchange recorded its highest-ever number of new listings. Nasdaq also had increasing trading volumes last year.

Further reading

Latest news


Latest news from FinansWatch (dk)

Latest news from EnergyWatch

Latest news from ShippingWatch